ST. LOUIS - Two new investigational smallpox vaccines will be studied as part of a clinical trial starting soon at Saint Louis University's Center for Vaccine Development. Saint Louis University is the only location in the United States participating in the trial.
The investigational vaccines, manufactured by Massachusetts-based Acambis Inc., will be compared with the existing smallpox vaccine, known as Dryvax. The new vaccines were produced using modern methods of cell cultivation. Dryvax, the same smallpox vaccine that was provided to all U.S. residents during the period of routine smallpox vaccination, hasn't been produced in many years.
"Although there has not been a case of smallpox in the United States since 1949, the U.S. government has determined that it is necessary to keep smallpox vaccine available, in case the disease is reintroduced through bioterrorism," said Sharon Frey, M.D., principal investigator for the study and associate professor of internal medicine in the division of infectious diseases at Saint Louis University School of Medicine. "A study starting this fall at Saint Louis University is being done to determine the effectiveness of two new investigational smallpox vaccines in healthy adults."
The study will include 90 adult volunteers: 30 receive one newly produced smallpox vaccine, 30 receive the other new vaccine and 30 will receive Dryvax. Like the two newly manufactured vaccines, Dryvax is also considered investigational because researchers will use a different "diluent" to change the vaccine from its dry state (how it's stored) to its liquid state (how it's administered).
"The effectiveness of these smallpox vaccines will be measured by observing whether or not a 'pock,' which resembles a blister, forms at the site of the vaccination, and through blood tests," Frey said. The pock is a typical response to smallpox vaccination and leaves a small scar or depression on the skin at the site of vaccination.
Volunteers must be between 18 and 29 years of age, generally in good health with no chronic illness, no heart disease, no history of serious allergic reaction, no immune system problems and no eczema or other significant skin conditions. Potential volunteers who have significant contact with anyone who is pregnant or with a child less than 12 months of age will be excluded. Volunteers must not previously have been vaccinated against smallpox.
Qualified volunteers will receive lab tests and vaccine at no charge and will be paid for time and travel.
For more information or to discuss volunteering, call the Saint Louis University Center for Vaccine Development at 314-977-6333.
Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first M.D. degree west of the Mississippi River. Saint Louis University School of Medicine is a pioneer in geriatric medicine, organ transplantation, chronic disease prevention, cardiovascular disease, neurosciences and vaccine research, among others. The School of Medicine trains physicians and biomedical scientists, conducts medical research, and provides health services on a local, national and international level.
The above post is reprinted from materials provided by Saint Louis University. Note: Materials may be edited for content and length.
Cite This Page: